Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 150

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 150
---
 devote
approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed
by Medica Venture Partners.

Dr. Eli Hazum, Chief Executive Officer

Dr. Eli Hazum has served
as our Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since
1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic
Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received
his Ph.D. degree in the field of hormone biochemistry from the Weizmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from
Tel Aviv University and an executive MBA degree from Humberside University in the UK.

<div align='center'>91</div>

Mr. Arie Gordashnikov, CPA, Chief Financial Officer

Mr. Arie Gordashnikov has
been our Chief Financial Officer since October 2022. He has served as Head of Initial Public Offering, or IPO, and Mergers and Acquisitions
Department at Shimony Yosef Certified Public Accountant (Isr.), or Shimony, since 2018. Mr. Gordashnikov has over 15 years’ experience
in accounting, auditing and finance of Hi-Tech and biotechnology companies. Before joining Shimony, Mr. Gordashnikov was an audit manager
at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management, a B.A. in Accounting
and Economics from Hebrew University of Jerusalem, and has been a licensed CPA since 2012.

Mr. Jeff Dykan, CPA, Director

Mr. Jeff Dykan has served
on our Board of Directors since 2005. He was appointed by our shareholder SCP Vitalife. Since 2002 Mr. Dykan has been a director of Vitalife
Partners Management LP, the general partner of Vitalife, and since 2007 has been a director of its successor fund, SCP Vitalife GP, the
corporate general partner of the common general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel)
II L.P. He has also served as a managing member of SCP Vitalife Management Company, LLC